Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7391MR)

This product GTTS-WQ7391MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7391MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15186MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ7164MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ8633MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ2180MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9114MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ13233MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ2720MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ3327MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW